Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial

Area of Science:

• Cardiology
• Vascular Biology
• Pharmacotherapy

Background:

• Saphenous vein grafts used in coronary artery bypass graft (CABG) surgery are prone to atherosclerotic disease progression.
• Controlling low-density-lipoprotein (LDL) cholesterol is crucial for managing cardiovascular disease.
• Previous guidelines recommended moderate LDL cholesterol lowering for post-CABG patients.

Purpose of the Study:

• To compare the efficacy of aggressive versus moderate LDL cholesterol lowering in preventing atherosclerosis in saphenous vein grafts.
• To evaluate the impact of individualized statin dosing on graft disease progression.

Main Methods:

• The Post-Coronary Artery Bypass Graft (CABG) trial enrolled patients receiving CABG surgery.
• Participants were randomized to either aggressive LDL lowering (<85 mg/dL) or moderate LDL lowering (130-140 mg/dL).
• Lovastatin dosages were titrated based on individual LDL cholesterol levels; graft atherosclerosis was assessed via angiography 4-5 years post-enrollment.

Main Results:

• Atherosclerotic disease progression occurred at a 31% lower rate in the aggressive LDL lowering group compared to the moderate group.
• Patient compliance with lovastatin therapy was high, ranging from 85-90% in both groups.
• Angiographic data confirmed a significant benefit of more intensive LDL cholesterol reduction.

Conclusions:

• Lowering LDL cholesterol to <100 mg/dL is recommended for patients with coronary artery disease.
• Aggressive LDL cholesterol lowering demonstrates superior efficacy in preventing saphenous vein graft atherosclerosis post-CABG.
• Ensuring adequate, individualized statin therapy is essential for at-risk cardiovascular patients.